gefitinib has been researched along with lignans in 2 studies
Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (lignans) | Trials (lignans) | Recent Studies (post-2010) (lignans) |
---|---|---|---|---|---|
5,231 | 566 | 2,919 | 7,024 | 95 | 4,172 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bai, P; Chen, L; Li, W; Luo, H; Peng, A; Tang, M; Wan, L; Wang, F; Wen, J; Wu, W; Yang, J; Yang, L; Yang, S; Ye, H; Zheng, L | 1 |
Feng, W; Xian, H; Zhang, J | 1 |
2 other study(ies) available for gefitinib and lignans
Article | Year |
---|---|
Liposomal honokiol induced lysosomal degradation of Hsp90 client proteins and protective autophagy in both gefitinib-sensitive and gefitinib-resistant NSCLC cells.
Topics: Animals; Antineoplastic Agents; Autophagy; Biphenyl Compounds; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Lignans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Signal Transduction | 2017 |
Schizandrin A enhances the efficacy of gefitinib by suppressing IKKβ/NF-κB signaling in non-small cell lung cancer.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclooctanes; Drug Synergism; Gefitinib; Humans; I-kappa B Kinase; Lignans; Lung Neoplasms; Molecular Dynamics Simulation; NF-kappa B; Polycyclic Compounds; Protein Conformation; Signal Transduction | 2019 |